Following the October 2026 introduction of EVErECM and EVE ARI, the South Korean company expands its professional aesthetic portfolio with lab-grown organoid ECM and multi-peptide formulations.
SEOUL, South Korea, Nov. 6, 2026 /PRNewswire-PRWeb/ -- Growing interest in advanced skin rejuvenation and targeted skincare solutions is encouraging the exploration of diverse ingredient technologies across the beauty and professional aesthetics industries. In South Korea, extracellular matrix (ECM)-based skin boosters are gaining attention as the industry explores approaches that go beyond individual active ingredients to consider the skin's structural environment. According to market analysis published by Shinhan Financial Group, the domestic ECM skin booster market is projected to grow from approximately KRW 92.5 billion in 2026 to KRW 172.9 billion in 2027.
Meanwhile, peptides are gaining momentum in the global skincare industry, supported by rising demand for anti-aging products, advances in peptide synthesis technologies, and their expanding use in multifunctional skincare formulations. According to Persistence Market Research, the global cosmetic peptide synthesis market is forecast to grow from USD 269.6 million in 2026 to USD 387.7 million by 2033, at a compound annual growth rate of 5.3%.
Reflecting these developments, BS PHARM KOREA has expanded its professional aesthetic portfolio with EVErECM and EVE ARI, introduced in October 2026. Built around distinct formulation concepts—lab-grown organoid ECM and a five-peptide complex—the two products demonstrate the company's approach to exploring emerging ingredient technologies and broadening its branded offerings for international distribution partners.
"With EVErECM and EVE ARI, we are expanding our portfolio to offer a broader range of formulation technologies for professional aesthetics," said a representative of BS PHARM KOREA. "Our focus is on introducing differentiated product concepts and building long-term relationships with international distribution partners."
EVErECM: A Lab-Grown Approach to Organoid ECM
EVErECM is a professional aesthetic solution developed around lab-grown organoid ECM technology. While some ECM materials are obtained from donor-derived biological tissues, EVErECM is developed using laboratory-grown three-dimensional tissue models designed to mimic characteristics of native human tissue. This approach introduces an alternative method of obtaining ECM materials without relying on donor-derived tissue.
The formulation contains 25 mg of organoid ECM, with an analyzed composition of 70% collagen, 20% proteoglycans, and 10% glycosaminoglycans (GAGs). Together, these components form EVErECM's Full-Matrix concept, combining multiple extracellular matrix constituents rather than focusing on a single structural ingredient.
The product also features a ready-to-use liquid format that requires no powder reconstitution. Its lab-grown origin, full-matrix composition, and controlled manufacturing approach are central to its formulation concept.
EVE ARI: A Multi-Peptide Approach to Expression-Related Skin Concerns
Alongside EVErECM, BS PHARM KOREA introduced EVE ARI, a professional aesthetic skin booster formulated with five functional peptides and sodium hyaluronate. Facial expression lines are associated with repeated muscle movements and the underlying neuromuscular signaling processes, making expression-related pathways an area of interest in peptide research.
EVE ARI features a 5-Peptide Complex that brings together ingredients studied for their relationships with different aspects of expression-related signaling, including pathways associated with neurotransmitter release and receptor interactions. Rather than relying on a single peptide concept, the formulation is designed around a combination of complementary peptide mechanisms.
Building on the growing interest in functional peptides across the skincare industry, EVE ARI introduces a mechanism-informed, multi-peptide formulation concept to BS PHARM KOREA's professional aesthetic portfolio, complementing its existing hydration-focused skin booster offerings.
Expanding a Technology-Driven Aesthetic Portfolio
With the addition of EVErECM and EVE ARI, BS PHARM KOREA continues to diversify its branded product portfolio beyond established hyaluronic acid, PN/PDRN, and exosome-based formulations.
The two launches represent the company's approach to incorporating a wider range of ingredient technologies into its professional aesthetic offerings. This expanded portfolio is intended to provide international distribution partners with more options to address evolving market preferences and product demands.
Supporting Global Distribution Partnerships
BS PHARM KOREA is introducing EVErECM and EVE ARI to international distributors and professional aesthetic business partners as part of its ongoing global market expansion strategy.
By broadening its portfolio with organoid ECM and peptide-based formulations, the company aims to support distributors seeking differentiated aesthetic product concepts for their respective markets.
BS PHARM KOREA will continue to strengthen its international business network through industry exhibitions, product marketing initiatives, and long-term distribution partnerships, subject to applicable market-specific regulatory requirements.
About BS PHARM KOREA
BS PHARM KOREA is a South Korea-based company specializing in professional aesthetic products for healthcare professionals and international distribution partners.
The company develops its branded product portfolio and supports global markets through product planning, international marketing, participation in medical aesthetics congresses, and long-term collaboration with distribution partners.
For more information, visit BS PHARM KOREA.
Media Contact
Marketing Manager, BS PHARM KOREA, 82 25117185, [email protected], https://www.bsp-korea.com
SOURCE BS PHARM KOREA
Share this article